Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
Objective:Patients with asymptomatic or minimally symptomatic Stage IV EGFR-positive NSCLC
with baseline intracranial metastases.
Aim: To investigate the timing, efficacy and safety of radiotherapy in patients with EGFR
positive brain metastases treated with armatinib alone or combined with stereotactic
radiotherapy.
Method: Almonertinib: specification 55mg/tablet; The dosage is 110 mg / day (2 tablets / day)
orally once a day; SBRT: 3-5 doses of 27-40 Gy